Day One Acquires Mersana for $25 per Share, Expanding Oncology Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Globenewswire
- Acquisition Completed: Day One successfully acquired Mersana, paying $25 per share in cash along with a non-tradable contingent value right per share, with potential milestone payments totaling up to $30.25 per CVR, thereby enhancing its strategic positioning in adult oncology.
- Pipeline Expansion: This acquisition adds the innovative antibody-drug conjugate Emi-Le targeting B7-H4 to Day One's clinical pipeline, aimed at treating the rare adenoid cystic carcinoma, addressing a significant unmet medical need in this area.
- Market Response: As of the tender offer expiration, a total of 3,029,135 shares of Mersana were validly tendered, representing 60.57% of outstanding shares, ensuring the smooth completion of the acquisition and further solidifying Day One's market position.
- Strategic Fit: Day One's CEO stated that this acquisition aligns closely with the company's mission, aiming to accelerate the development of new therapies by integrating resources, thereby enhancing its impact on patient communities and achieving sustainable business growth.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
